تحميل
NASDAQHealthcareMedical - Instruments & Supplies
أحدث البيانات المتاحة
3.92 US$
+0.02 US$ · +0.51%
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
عند الإغلاق
3.92 US$
+0.02 US$ · +0.51%
بعد ساعات التداول
3.92 US$
0.00 US$ · 0.00%
12 أكتوبر، 4:14 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
نطاق اليوم
السعر الحالي 3.92 US$
نطاق 52 أسبوعًا
السعر الحالي 3.92 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
47
قيمة عادلة
المشاعر
57
مختلط
المخاطر
41
مخاطر أعلى من المعتاد
الزخم
61
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
نطاق اليوم
السعر الحالي 3.92 US$
نطاق 52 أسبوعًا
السعر الحالي 3.92 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
4.00 US$
ارتفاع محتمل بنسبة 2.04%سجل الأسعار غير متاح
عالي: 4.00 US$متوسط: 4.00 US$قليل: 4.00 US$| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 8 أبريل 1987 | 3:1 | — | — |
ساري 8 أبريل 1987
3:1
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI7.71 مليون0.00%2.3 ترليون USD0.03%381.57 US$-0.10%
iShares Russell 2000 ETFIWM6.47 مليون0.01%78.74 مليار USD0.19%277.9 US$-0.37%
Vanguard Extended Market ETFVXF2.89 مليون0.00%95.4 مليار USD0.05%233.52 US$-0.63%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2.52 مليون0.01%26.81 مليار USD0.33%37.98 US$+0.08%
Dimensional - US Small Cap ETFDFAS2.09 مليون0.01%33.87 مليار USD0.31%78.17 US$-0.23%
Vanguard Russell 2000 ETFVTWO1.35 مليون0.01%18 مليار USD0.06%112.27 US$-0.35%
Schwab U.S. Small-Cap ETFSCHA1.31 مليون0.01%21.82 مليار USD0.03%32.66 US$-0.40%
Dimensional - US Core Equity 2 ETFDFAC1.03 مليون0.00%88.6 مليار USD0.21%45.31 US$-0.04%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSVDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Core Equity 2 ETFDFACالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
